{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/COV.AU"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"COV.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"COV.AU\",,,,,undefined,":{"symbol":"COV.AU","market":"AU","secType":"STK","nameCN":"Cleo Diagnostics Ltd","latestPrice":0.395,"timestamp":1746511920000,"preClose":0.39,"halted":0,"volume":12598,"delay":0,"nameEN":"Cleo Diagnostics Ltd","floatShares":73005001,"shares":128500001,"eps":-0.02832,"marketStatus":"Closed","change":0.005,"latestTime":"05-06 16:12:00 AEST","open":0.395,"high":0.395,"low":0.39,"amount":4976,"amplitude":0.012821,"askPrice":0.395,"askSize":64101,"bidPrice":0.385,"bidSize":16300,"shortable":3,"etf":0,"ttmEps":-0.02832,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1746576000000},"marketStatusCode":5,"adr":0,"listingDate":1692540000000,"exchange":"ASX","adjPreClose":0.39,"openAndCloseTimeList":[[1746489600000,1746511200000]],"volumeRatio":0.287612,"lotSize":0,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"COV.AU\",,,,,undefined,":{"symbol":"COV.AU","floatShares":73005001,"roa":"-21.46%","roe":"-34.46%","lyrEps":-0.032042,"volumeRatio":0.287612,"shares":128500001,"dividePrice":0,"high":0.395,"amplitude":0.012821,"preClose":0.39,"low":0.39,"week52Low":0.16,"pbRate":"6.82","psRate":"240.77","week52High":0.62,"institutionHeld":0,"latestPrice":0.395,"committee":-0.594532,"eps":-0.02832,"divideRate":0,"volume":12598,"delay":0,"ttmEps":-0.02832,"open":0.395,"prevYearClose":0.355,"prevWeekClose":0.407,"prevMonthClose":0.41,"prevQuarterClose":0.35,"fiveDayClose":0.405,"twentyDayClose":0.37,"sixtyDayClose":0.36},"@#url:\"https://hq.skytigris.cn/market/plate/belongs/COV.AU\",params:#limit:6,delay:false,,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"COV.AU\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2525088519","title":"BirdDog Technology Among 3 ASX Penny Stocks To Watch","url":"https://stock-news.laohu8.com/highlight/detail?id=2525088519","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525088519?lang=en_us&edition=fundamental","pubTime":"2025-04-08 10:04","pubTimestamp":1744077899,"startTime":"0","endTime":"0","summary":"Australian shares are experiencing a slight rebound, climbing around 0.5% after a significant one-day loss not seen since May 2020, as the market recalibrates following recent volatility. Amidst these fluctuations, investors often seek opportunities that balance potential growth with financial resilience. Penny stocks, though sometimes considered relics of past trading days, remain relevant for those looking to uncover hidden value in smaller or newer companies with strong financial foundations. In this article, we explore three such penny stocks on the ASX that stand out for their promising potential and robust balance sheets.BirdDog Technology Limited, with a market cap of A$7.43 million, is navigating financial challenges as it remains unprofitable with increasing losses over the past five years. Despite short-term assets exceeding liabilities and being debt-free, the company has less than a year of cash runway and experiences high share price volatility. Recent earnings show reduce","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/birddog-technology-among-3-asx-020459612.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["XKO.AU","BDT.AU","CWP.AU","BK7021","BIS.AU","BK7104","BK7098","RPL.AU","XAO.AU","CLX.AU","BK7045","BK7048","SXE.AU","EZZ.AU","BK7509","IGL.AU","BK7058","MDX.AU","BK7055","GTN.AU","BK7062","SHA.AU","COV.AU","AX1.AU","BK7129","BK7145","XJO.AU","BK7067"],"gpt_icon":0},{"id":"2520965613","title":"Cleo Diagnostics Starts Transfer Activities to Develop Ovarian Cancer Detection Blood Test","url":"https://stock-news.laohu8.com/highlight/detail?id=2520965613","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520965613?lang=en_us&edition=fundamental","pubTime":"2025-03-19 08:39","pubTimestamp":1742344760,"startTime":"0","endTime":"0","summary":"Cleo Diagnostics  started the technology transfer activities to develop its blood test designed for early detection of ovarian cancer, according to a Tuesday filing with the Australian bourse.The technology transfer includes the transfer of its in-house development activities to a manufacturer to support commercial production, the filing said.Accordingly, the company has partnered with US-based R&D Systems, a unit of Bio-Techne Group, to handle pre-production kit assembly and testing, the filing added.After successful testing, a selected contract manufacturing organization  will expand production and complete verification and validation to produce in-vitro diagnostic kits for clinical use, the company said.Final negotiations with US Food and Drug Administration-approved CMOs are underway, with the selection based on manufacturing capacity and regulatory compliance, the company added.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CMO.AU","COV.AU","BK7095"],"gpt_icon":0},{"id":"2520637155","title":"CLEO Diagnostics kicks off IP transfer for ovarian cancer blood tests to US manufacturers","url":"https://stock-news.laohu8.com/highlight/detail?id=2520637155","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520637155?lang=en_us&edition=fundamental","pubTime":"2025-03-18 09:24","pubTimestamp":1742261040,"startTime":"0","endTime":"0","summary":"CLEO Diagnostics , a company developing a simple blood test for ovarian cancer for use in surgical triage, has commenced the “technology transfer” process to a U.S.-based manufacturing partner ahead of commercialisation.Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.In the background, it’s receiving advisory assistance from U.S.-based R&D Systems Inc, an immunoassay technology giant part of the Bio-Techne Group eventually responsible for mass producing the antibodies Cleo’s tech relies on. That is to whom technology transfer has begun.In between the lines, it sounds like the ‘technology transfer’ is in the very early stages and Cleo mightn’t know who it’s going with just yet.The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/cleo-diagnostics-kicks-off-ip-transfer-for-ovarian-cancer-blood-tests-to-us-manufacturers-2025-03-18/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK4585","LU1481599808.USD","IP","BK4136","LU1481600234.SGD","BK4588","LU2463526074.USD","LU1487256676.USD","COV.AU"],"gpt_icon":0},{"id":"2486185968","title":"Cleo adds Royal Women’s Hospital to its clinical trial for ovarian cancer diagnosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2486185968","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486185968?lang=en_us&edition=fundamental","pubTime":"2024-11-27 07:23","pubTimestamp":1732663380,"startTime":"0","endTime":"0","summary":"Cleo Diagnostics Ltd  has expanded its clinical trials for a simple blood test to detect ovarian cancer, with the Royal Women’s Hospital in Melbourne joining as a participating site, and noted gynaecological oncology specialist Associate Professor OrlaMcNally becoming Principal Investigator.The addition of the hospital will offer a number of benefits to the trial: not only expanding its cohort of patients to sample from, but boosting market awareness of the trial and of Cleo – given that the Royal Women’s is Australia’s leading specialist hospital for women’s health.Cleo is also progressing a US clinical trial which is set to facilitate its submission to the Food and Drug Administration  which is on-track for the 2025 calendar year, with patient recruitment ongoing across eight sites, and an expected 500 people to take part.Royal Women’s Hospital Director of Oncology Associate Professor Orla McNally said the Australian trial would be a boon for diagnosis of ovarian cancer.Join the disc","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/cleo-adds-royal-womens-hospital-to-its-clinical-trial-for-ovarian-cancer-diagnosis-2024-11-27/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK4588","RGLD","COV.AU","BK4585","LU0345780281.USD","BK4017","LU0345780521.USD"],"gpt_icon":0}],"pageSize":4,"totalPage":1,"pageCount":1,"totalSize":4,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/COV.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"COV.AU\",market:\"AU\",,,undefined,":[]}}